Abstract:Background: Rare endocrine cancers such as Adrenocortical Carcinoma (ACC) present a serious diagnostic and prognostication challenge. The knowledge about ACC pathogenesis is incomplete, and patients have limited therapeutic options. Identification of molecular drivers and effective biomarkers is required for timely diagnosis of the disease and stratify patients to offer the most beneficial treatments. In this study we demonstrate how machine learning methods integrating multi-omics data, in combination with system biology tools, can contribute to the identification of new prognostic biomarkers for ACC. Methods: ACC gene expression and DNA methylation datasets were downloaded from the Xena Browser (GDC TCGA Adrenocortical Carcinoma cohort). A highly correlated multi-omics signature discriminating groups of samples was identified with the data integration analysis for biomarker discovery using latent components (DIABLO) method. Additional regulators of the identified signature were discovered using Clarivate CBDD (Computational Biology for Drug Discovery) network propagation and hidden nodes algorithms on a curated network of molecular interactions (MetaBaseTM). The discriminative power of the multi-omics signature and their regulators was delineated by training a random forest classifier using 55 samples, by employing a 10-fold cross validation with five iterations. The prognostic value of the identified biomarkers was further assessed on an external ACC dataset obtained from GEO (GSE49280) using the Kaplan-Meier estimator method. An optimal prognostic signature was finally derived using the stepwise Akaike Information Criterion (AIC) that allowed categorization of samples into high and low-risk groups. Results: A multi-omics signature including genes, micro RNA's and methylation sites was generated. Systems biology tools identified additional genes regulating the features included in the multi-omics signature. RNA-seq, miRNA-seq and DNA methylation sets of features revealed a high power to classify patients from stages I-II and stages III-IV, outperforming previously identified prognostic biomarkers. Using an independent dataset, associations of the genes included in the signature with Overall Survival (OS) data demonstrated that patients with differential expression levels of 8 genes and 4 micro RNA's showed a statistically significant decrease in OS. We also found an independent prognostic signature for ACC with potential use in clinical practice, combining 9-gene/micro RNA features, that successfully predicted high-risk ACC cancer patients. Conclusion: Machine learning and integrative analysis of multi-omics data, in combination with Clarivate CBDD systems biology tools, identified a set of biomarkers with high prognostic value for ACC disease. Multi-omics data is a promising resource for the identification of drivers and new prognostic biomarkers in rare diseases that could be used in clinical practice.

High expression of GMNN predicts malignant progression and poor prognosis in ACC

Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma

Identification and validation of a novel prognosis prediction model in adrenocortical carcinoma by integrative bioinformatics analysis and statistics and machine learning

Molecular Cluster Mining of Adrenocortical Carcinoma Via Multi-Omics Data Analysis Aids Precise Clinical Therapy.

Comprehensive Multiomics Analysis Reveals Potential Diagnostic and Prognostic Biomarkers in Adrenal Cortical Carcinoma

Identification of hub genes and pathways in adrenocortical carcinoma by integrated bioinformatic analysis

Identification of Five Genes as a Potential Biomarker for Predicting Progress and Prognosis in Adrenocortical Carcinoma

Identification and Validation of a Novel Prognosis Prediction Model in Adrenocortical Carcinoma by Integrative Bioinformatics Analysis, Statistics, and Machine Learning

Co-expression Network Analysis of Biomarkers for Adrenocortical Carcinoma

Identification of immune-related biomarkers in adrenocortical carcinoma Immune-related biomarkers for ACC

Establishment and Validation of a Gene Signature-Based Prognostic Model to Improve Survival Prediction in Adrenocortical Carcinoma Patients

Identification of Key Genes and Related Drugs of Adrenocortical Carcinoma by Integrated Bioinformatics Analysis.

High TNFSF13B Expression As a Predictor of Poor Prognosis in Adrenocortical Carcinoma

Machine learning combining multi-omics data and network algorithms identifies adrenocortical carcinoma prognostic biomarkers

Analysis of M6a-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.

Bioinformatic Analyses and Experimental Validation of the Role of M6a RNA Methylation Regulators in Progression and Prognosis of Adrenocortical Carcinoma.

A Hypoxia Signature for Predicting Prognosis and Tumor Immune Microenvironment in Adrenocortical Carcinoma

Expression of FSCN1 and FOXM1 Are Associated with Poor Prognosis of Adrenocortical Carcinoma Patients

Identification of an Immune‐related Gene Signature As a Prognostic Target and the Immune Microenvironment for Adrenocortical Carcinoma

Identification and Functional Analysis of Novel Biomarkers in Adenoid Cystic Carcinoma.

Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival